| scholarly article | Q13442814 |
| P50 | author | Trent M. Woodruff | Q47504524 |
| P2093 | author name string | Jessy J Alexander | |
| James N Jarvis | |||
| Richard J Quigg | |||
| Stanley A Schwartz | |||
| Molly Lopez | |||
| Supriya D Mahajan | |||
| Teresa Hennon | |||
| Neil U Parikh | |||
| Patrick Cunningham | |||
| P2860 | cites work | Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration | Q28249885 |
| Molecular organization and function of the complement system | Q28289114 | ||
| Getting to the site of inflammation: the leukocyte adhesion cascade updated | Q29547271 | ||
| ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton | Q30157199 | ||
| Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis | Q30884724 | ||
| The blood-brain barrier in systemic lupus erythematosus | Q30887274 | ||
| Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice | Q31002573 | ||
| Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease | Q33489732 | ||
| Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse | Q33676881 | ||
| Blood-brain barrier structure and function and the challenges for CNS drug delivery | Q38100970 | ||
| Assessments of tight junction proteins occludin, claudin 5 and scaffold proteins ZO1 and ZO2 in endothelial cells of the rat blood-brain barrier: cellular responses to neurotoxicants malathion and lead acetate. | Q39640821 | ||
| Molecular Biology and Chemistry of the Alternative Pathway of Complement | Q40098618 | ||
| Rac1 regulates interleukin 1-induced nuclear factor kappaB activation in an inhibitory protein kappaBalpha-independent manner by enhancing the ability of the p65 subunit to transactivate gene expression | Q40903259 | ||
| IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway | Q41050922 | ||
| p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. | Q41062073 | ||
| Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis | Q41279731 | ||
| Complement and the immune response | Q41353179 | ||
| Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. | Q41976321 | ||
| Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats | Q43179116 | ||
| Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes | Q44387171 | ||
| Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis | Q45285415 | ||
| A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription | Q46114085 | ||
| Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. | Q46262655 | ||
| Tight junction regulation by morphine and HIV-1 tat modulates blood-brain barrier permeability | Q46522622 | ||
| Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus | Q47428719 | ||
| Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme | Q47929273 | ||
| Absence of functional alternative complement pathway alleviates lupus cerebritis | Q48157307 | ||
| Alterations in tight junction protein and IgG permeability accompany leukocyte extravasation across the choroid plexus during neuroinflammation | Q48494356 | ||
| An improved colorimetric assay for interleukin 2. | Q50906708 | ||
| The role of complement and complement receptors in induction and regulation of immunity. | Q53992218 | ||
| Complement activation and vascular injury in systemic lupus erythematosus | Q57731130 | ||
| Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease | Q57731137 | ||
| Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement | Q67569108 | ||
| Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Lack of correlation with levels of circulating vascular cell adhesion mo | Q72074312 | ||
| Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system | Q73471627 | ||
| Akt-dependent enhanced migratory capacity of Th17 cells from children with lupus nephritis | Q85844477 | ||
| The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. | Q33748190 | ||
| Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus | Q33765429 | ||
| Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease | Q33793485 | ||
| C5a alters blood-brain barrier integrity in experimental lupus | Q33868735 | ||
| Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier | Q33956446 | ||
| How to measure drug transport across the blood-brain barrier | Q33985116 | ||
| Inhibition of C5a receptor alleviates experimental CNS lupus | Q33985628 | ||
| Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles | Q33994463 | ||
| C3aR inhibition reduces neurodegeneration in experimental lupus | Q34187724 | ||
| Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. | Q34276891 | ||
| Endothelial histamine H1 receptor signaling reduces blood-brain barrier permeability and susceptibility to autoimmune encephalomyelitis. | Q34279208 | ||
| Neurologic manifestations of systemic lupus erythematosus in children and adults | Q34310715 | ||
| Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus. | Q34753885 | ||
| The physiology of leukocyte recruitment: an in vivo perspective. | Q34775612 | ||
| New regulators of NF-kappaB in inflammation | Q34858737 | ||
| Complement in central nervous system inflammation | Q34981854 | ||
| The role of the anaphylatoxins in health and disease | Q34983578 | ||
| Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. | Q35028480 | ||
| Differential roles of ICAM-1 and VCAM-1 in leukocyte-endothelial cell interactions in skin and brain of MRL/faslpr mice | Q35227677 | ||
| C5a/CD88 signaling alters blood-brain barrier integrity in lupus through nuclear factor-κB | Q35552398 | ||
| TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. | Q35688684 | ||
| Mitogen-activated protein kinases in apoptosis regulation | Q35743118 | ||
| Expression of Tight Junction and Drug Efflux Transporter Proteins in an in vitro Model of Human Blood-Brain Barrier | Q35952488 | ||
| The role of blood-brain barrier studies in the pharmaceutical industry | Q36393471 | ||
| The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. | Q36915584 | ||
| Evolving functions of endothelial cells in inflammation | Q36950913 | ||
| Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis | Q37206724 | ||
| Theranostic quantum dots for crossing blood-brain barrier in vitro and providing therapy of HIV-associated encephalopathy | Q37310114 | ||
| Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of cellular junctions | Q37524262 | ||
| Functional roles for C5a and C5aR but not C5L2 in the pathogenesis of human and experimental cerebral malaria | Q37548166 | ||
| Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke | Q37612249 | ||
| Transcriptional control of the inflammatory response | Q37622051 | ||
| In vitro models of the blood-brain barrier | Q37866093 | ||
| Patented in vitro blood-brain barrier models in CNS drug discovery. | Q37876433 | ||
| P433 | issue | 1 | |
| P921 | main subject | blood–brain barrier | Q221694 |
| P304 | page(s) | 130-143 | |
| P577 | publication date | 2015-07-15 | |
| P1433 | published in | Immunology | Q15754984 |
| P1476 | title | C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus | |
| P478 | volume | 146 |
| Q38406678 | All- Trans-Retinoic Acid Augments the Histopathological Outcome of Neuroinflammation and Neurodegeneration in Lupus-Prone MRL/lpr Mice |
| Q90312411 | Autoantibodies in Neuropsychiatric Disorders |
| Q47871567 | C5a induces caspase-dependent apoptosis in brain vascular endothelial cells in experimental lupus |
| Q47653397 | Complement Receptor C5aR1 Plays an Evolutionarily Conserved Role in Successful Cardiac Regeneration. |
| Q48662976 | Complement activation, a threat to pregnancy |
| Q63916924 | Deletion of Biliverdin Reductase A in Myeloid Cells Promotes Chemokine Expression and Chemotaxis in Part via a Complement C5a--C5aR1 Pathway |
| Q42102188 | Differential activation mechanisms of serum C5a in lupus nephritis and neuropsychiatric systemic lupus erythematosus |
| Q38991026 | Endothelial cells: source, barrier, and target of defensive mediators |
| Q59808939 | From Systemic Inflammation to Neuroinflammation: The Case of Neurolupus |
| Q90062401 | High Concentration of C5a-Induced Mitochondria-Dependent Apoptosis in Murine Kidney Endothelial Cells |
| Q55313873 | High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation. |
| Q47604007 | Immunomodulatory Role of Complement Proteins in the Neuropathology Associated with Opiate Abuse and HIV-1 Co-Morbidity |
| Q50116104 | Relationship between G proteins coupled receptors and tight junctions |
| Q39253402 | The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface |
Search more.